Use of aromatase inhibitors to treat endometriosis-related pain symptoms: a systematic review
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
This systematic review aims to assess the efficacy of aromatase inhibitors (AIs) in treating pain symptoms caused by endometriosis. A comprehensive literature search was conducted to identify all the published studies evaluating the efficacy of type II nonsteroidal aromatase inhibitors (anastrozole and letrozole) in treating endometriosis-related pain symptoms. The MEDLINE, EMBASE, PubMed, and SCOPUS databases and the Cochrane System Reviews were searched up to October 2010. This review comprises of the results of 10 publications fitting the inclusion criteria; these studies included a total of 251 women. Five studies were prospective non-comparative, four were randomized controlled trials (RCTs) and one was a prospective patient preference trial. Seven studies examined the efficacy of AIs in improving endometriosis-related pain symptoms, whilst three RCTs investigated the use of AIs as post-operative therapy in preventing the recurrence of pain symptoms after surgery for endometriosis. All the observational studies demonstrated that AIs combined with either progestogens or oral contraceptive pill reduce the severity of pain symptoms and improve quality of life. One patient preference study demonstrated that letrozole combined with norethisterone acetate is more effective in reducing pain and deep dyspareunia than norethisterone acetate alone. However, letrozole causes a higher incidence of adverse effects and does not improve patients' satisfaction or influence recurrence of symptoms after discontinuation of treatment. A RCT showed that combining letrozole with norethisterone acetate causes a lower incidence of adverse effects and lower discontinuation rate than combining letrozole with triptorelin. Two RCTs demonstrated that, after surgical treatment of endometriosis, the administration of AIs combined with gonadotropin releasing hormone analogue for 6 months reduces the risk of endometriosis recurrence when compared with gonadotropin releasing hormone analogue alone. In conclusion, AIs effectively reduce the severity of endometriosis-related pain symptoms. Since endometriosis is a chronic disease, future investigations should clarify whether the long-term administration of AIs is superior to currently available endocrine therapies in terms of improvement of pain, adverse effects and patient satisfaction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Some clinical studies have shown that third- generation nonsteroidal AIs, such as letrozole and anastrozole, effectively reduced the severity of endometriosis-related pain symptoms; however, their use is limited by several adverse events, such as bone and joint pain, muscle aches, and fatigue [277].”
From Hormonal treatments for endometriosis: The endocrine background (2022) · cites this paper as [277]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Some clinical studies have shown that third- generation nonsteroidal AIs, such as letrozole and anastrozole, effectively reduced the severity of endometriosis-related pain symptoms; however, their use is limited by several adverse events, such as bone and joint pain, muscle aches, and fatigue [277].”
From Hormonal treatments for endometriosis: The endocrine background (2022) · cites this paper as [277]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis of Observational Studies in Epidemiology<SUBTITLE>A Proposal for Reporting</SUBTITLE>
Stroup, D. F. (2000) · JAMA · doi:10.1001/jama.283.15.2008 · Cited by 20,623
Revised American Society for Reproductive Medicine classification of endometriosis: 1996
American Society for Reproductive Medicine (1997) · Fertility and Sterility · doi:10.1016/s0015-0282(97)81391-x · Cited by 3,018
Aromatase expression in endometriosis.
Noble, L. S., Simpson, E. R., Johns, A., & Bulun, S. E. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.1.8550748 · Cited by 566 · cited 1×
“Since the late 1990s, several independent studies based either on polymerase chain reaction or immunohistochemistry have demonstrated that aromatase P450 is over-expressed in both eutopic and ectopic endometrium of patients with endometriosis, while this enzyme is not detectable in eutopic endometrium obtained from he…”
BackgroundKitawaki, J., Noguchi, T., Amatsu, T., Maeda, K., Tsukamoto, K., Yamamoto, T., Fushiki, S., Osawa, Y., & Honjo, H. (1997) · Biology of Reproduction · doi:10.1095/biolreprod57.3.514 · Cited by 305 · cited 1×
“Since the late 1990s, several independent studies based either on polymerase chain reaction or immunohistochemistry have demonstrated that aromatase P450 is over-expressed in both eutopic and ectopic endometrium of patients with endometriosis, while this enzyme is not detectable in eutopic endometrium obtained from he…”
BackgroundUse of a levonorgestrel-releasing intrauterine device in the treatment of rectovaginal endometriosis
Fedele, L., Bianchi, S., Zanconato, G., Portuese, A., & Raffaelli, R. (2001) · Fertility and Sterility · doi:10.1016/s0015-0282(00)01759-3 · Cited by 290 · cited 1×
“Endometriosis is a chronic disease [48] and pain typically recurs to a degree similar to that at baseline after discontinuation of endocrine therapies [49,50].”
BackgroundTreatment of severe postmenopausal endometriosis with an aromatase inhibitor
Takayama, K., Zeitoun, K., Gunby, R. T., Sasano, H., Carr, B. R., & Bulun, S. E. (1998) · Fertility and Sterility · doi:10.1016/s0015-0282(98)00022-3 · Cited by 270 · cited 1×
“Of the 28 studies found, 4 were excluded because they were only published in the abstracts or proceedings of scientific meetings [20-23], 12 were excluded because they were case reports or included less than 10 patients [24-35], 1 study was excluded because of duplicate publication [36] and 1 study was excluded becaus…”
BackgroundPatients’ report on how endometriosis affects health, work, and daily life
Fourquet, J., Gao, X., Zavala, D., Orengo, J. C., Abac, S., Ruiz, A., Laboy, J., & Flores, I. (2010) · Fertility and Sterility · doi:10.1016/j.fertnstert.2009.09.017 · Cited by 252 · cited 1×
“In some patients, pain symptoms are extremely severe and negatively affect quality of life, work efficiency and sexual life [2-4].”
BackgroundAilawadi, R. K., Jobanputra, S., Kataria, M., Gurates, B., & Bulun, S. E. (2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.09.029 · Cited by 236 · cited 8×
“peer-reviewed journals between 2004 and October 2010 [38-47].”
BackgroundInfluentialSoysal, S. (2004) · Human Reproduction · doi:10.1093/humrep/deh035 · Cited by 227 · cited 17×
“Three studies investigated the use of AIs as postoperative therapy in preventing the recurrence of pain after surgical treatment of endometriosis [39,45,46]; seven studies examined the effect of AIs in improving endometriosis-related pain symptoms.”
BackgroundMethodInfluentialAnastrazole and oral contraceptives: a novel treatment for endometriosis
Amsterdam, L. L., Gentry, W., Jobanputra, S., Wolf, M., Rubin, S. D., & Bulun, S. E. (2005) · Fertility and Sterility · doi:10.1016/j.fertnstert.2005.02.018 · Cited by 219 · cited 7×
“[40] 2005 Prospective noncomparative trial 18 23-46 surgery NA oral: anastrozole 1 mg/day oral: ethinyl estradiol 20 μg/day, levonorgestrel 0.”
BackgroundInfluential
Research works printed but not linked: 1
- 10.1210/jc.81.1.174 · DOI · Paper page
Cited by
Zondervan, K. T., Becker, C. M., & Missmer, S. A. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1810764 · Cited by 2,249
ESHRE guideline: management of women with endometriosis
Dunselman, G. A. J., Vermeulen, N., Becker, C., Calhaz-Jorge, C., D'Hooghe, T., De Bie, B., Heikinheimo, O., Horne, A. W., Kiesel, L., Nap, A., et al. (2014) · Human Reproduction · doi:10.1093/humrep/det457 · Cited by 2,211
“…endometriosis, refractory to other medical or surgical treatment, clinicians can consider prescribing aromatase inhibitors in combination with oral contraceptive pills, progestagens or GnRH analogues, as they reduce endometriosis-associated pain (Nawathe et al., 2008; Ferrero et al., 2011).”
BackgroundESHRE guideline: endometriosis
Becker, C. M., Bokor, A., Heikinheimo, O., Horne, A., Jansen, F., Kiesel, L., King, K., Kvaskoff, M., Nap, A., Petersen, K., et al. (2022) · Human Reproduction Open · doi:10.1093/hropen/hoac009 · Cited by 1,712
“Aromatase inhibitors may be prescribed in combination with oral contraceptives, progestogens, GnRH agonists or GnRH antagonists (Ferrero et al. , 2011; Almassinokiani et al. , 2014; Agarwal and Foster, 2015).”
Self-citationConsensus on current management of endometriosis
Johnson, N. P., Hummelshoj, L., for the World Endometriosis Society Montpellier Consortium, Abrao, M. S., Adamson, G. D., Allaire, C., Amelung, V., Andersson, E., Becker, C., Birna Árdal, K. B., et al. (2013) · Human Reproduction · doi:10.1093/humrep/det050 · Cited by 558
“…ic.oup.com /hum rep/article-abstract/28/6/1552/603470 by guest on 16 M arch 2020 (anastrazole, fadrozole, formestane, exemestane, letrozole) (Ferrero et al., 2011), selective progesterone receptor modulator (mifepristone, ulipristal) (Guo et al., 2011) and orally active GnRH antagonists…”
BackgroundHormonal treatments for endometriosis: The endocrine background
Vannuccini, S., Clemenza, S., Rossi, M., & Petraglia, F. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09666-w · Cited by 336
Metadata
- Authors
- Ferrero, S., Gillott, D. J., Venturini, P. L., & Remorgida, V.
- Affiliations
- Queen Mary University of London (GB)
- Ospedale Policlinico San Martino (IT)
- Corresponding author
- Ferrero, Simone
- Venue
- Reproductive Biology and Endocrinology
- Published
- 2011
- Volume
- 9
- Issue
- 1
- Pages
- 89
- ISSN
- 1477-7827 (ISSN-L)
- PMC
- PMC3141646
- OpenAlex
- W2103212783
- Cited by
- 109
- References
- 56
- Citations by year
- 2026: 7 · 2025: 5 · 2024: 4 · 2023: 9 · 2022: 7 · 2021: 8 · 2020: 8 · 2019: 10 · 2018: 6 · 2017: 9 · 2016: 3 · 2015: 8 · 2014: 9 · 2013: 8 · 2012: 7
- FWCI
- 1.23
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Reproductive Biology and Endocrinology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Health Sciences › Medicine › Obstetrics and Gynecology › Ectopic Pregnancy Diagnosis and Management
- Health Sciences › Medicine › Obstetrics and Gynecology › Gynecological conditions and treatments
- Keywords
- endometriosis, aromatase inhibitors, anastrozole, letrozole, dyspareunia, endometriosis-associated pain, postoperative recurrence prevention, GnRH analogues, triptorelin, norethisterone acetate, progestogens, oral contraceptives, endocrine therapy, adverse effects, quality of life
- MeSH terms
- Letrozole, Anastrozole, Clinical Trials as Topic, Endometriosis, Female, Humans, Nitriles, Postoperative Pain, Triazoles, Pelvic Pain, Aromatase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Use of aromatase inhibitors to treat endometriosis-related pain symptoms: a systematic review. https://app.cochat.ai/papers/10.1186/1477-7827-9-89
- The paper
- Ferrero, S., Gillott, D. J., Venturini, P. L., & Remorgida, V. (2011). Use of aromatase inhibitors to treat endometriosis-related pain symptoms: a systematic review. Reproductive Biology and Endocrinology. https://doi.org/10.1186/1477-7827-9-89
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
